Annals of Oncology Advance Access published online on October 3, 2006
Annals of Oncology, doi:10.1093/annonc/mdl327
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Haematology, General Hospital St Georg, Hamburg, Germany
* To whom correspondence should be addressed. Background: Central nervous system (CNS) relapse is a devastating and usually fatal complication of aggressive lymphoma. The extent of the disease, the proliferation rate and the sites of extranodal involvement have been discussed as risk factors. We analyzed the patients treated on protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) between 1990 and 2000, evaluated the rate and prognostic factors for CNS recurrence and developed a risk model trying to identify subsets of patients suitable for future prophylactic strategies. Patients and methods: From 1993 to 2000, 1399 patients [ Results: A total number of 1711 patients were initially eligible for this study, of whom 18 patients had to be excluded due to primary CNS involvement. In the remaining 1693 assessable patients, 37 cases of relapse or progression to the CNS (2.2%) were observed. The protocol asked for an intrathecal (i.th.) prophylaxis in patients with lymphoblastic lymphoma only (n = 17), but overall 71 patients (71 of 1693 = 4.2%) received prophylaxis by decision of the treating physicians. Multivariate Cox regression analysis identified increased LDH (P < 0.001) and involvement of more than one extranodal site (P = 0.002) as independent predictors of CNS recurrence in the NHL-B1/B2 study population. Treatment with etoposide also evolved as a prognostic factor because the risk of CNS failure was significantly reduced after CHOEP (P = 0.017). Elderly patients presenting with both an elevated LDH and lymphoma involvement in liver, bladder or adrenals had an up to 15-fold risk of spread of the disease to the CNS. Conclusion: The incidence of CNS relapse in 1693 patients treated for aggressive lymphomas on DSHNHL protocols from 1990 to 2000 was low (2.2%), although CNS prophylaxis was administered to <5% of patients. Thus, a general prophylaxis for all patients is not warranted, the less so since the effectiveness of i.th. prophylaxis itself is judged controversially. Increased LDH and involvement of more than one extranodal site were confirmed as independent risk factors. A cumulative 20% incidence of CNS disease in certain prognostic subgroups of elderly patients may render these candidates for i.th. prophylaxis; however, this approach would imply a potential overtreatment of
Received March 7, 2006
Revised July 10, 2006
Accepted August 10, 2006
original article
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
V. Boehme 1 *, S. Zeynalova 2, M. Kloess 2, M. Loeffler 2, U. Kaiser 3, M. Pfreundschuh 4, and N. Schmitz 1
2 Institute of Medical Informatics, Statistics and Epidemiology, University Leipzig, Germany
3 Medical Department of Haematology, St Bernward Hospital, Hildesheim, Germany
4 Department of Internal Medicine I, Saarland University, Homburg/Saar, Germany
V. Boehme, E-mail: volkmar.boehme{at}ak-stgeorg.lbk-hh.de
Abstract 
60 years with normal lactate dehydrogenase (LDH) and >60 years irrespective of LDH] were randomized to receive six cycles of combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-21, CHOP-14 or six cycles of CHOP + etoposide (CHOEP)-21, CHOEP-14 in a 2 x 2 factorial study design in the NHL-B1/B2 studies. From 1990 to 1997, 312 patients 60 years with an elevated LDH were randomized to five cycles CHOEP + involved field (IF) radiotherapy or three cycles CHOEP followed by high-dose BCNU, etoposide, cytarabine and melphalan (BEAM) and autologous stem-cell transplantation (NHL-A study).
80% of these patients deemed at high risk.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Villa, J. M. Connors, T. N. Shenkier, R. D. Gascoyne, L. H. Sehn, and K. J. Savage Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy Ann. Onc., October 27, 2009; (2009) mdp432v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Kim, S. Y. Oh, J. Y. Hong, M. H. Chang, D. H. Lee, J. Huh, Y. H. Ko, Y. C. Ahn, H.-J. Kim, C. Suh, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann. Onc., October 22, 2009; (2009) mdp412v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Boehme, N. Schmitz, S. Zeynalova, M. Loeffler, and M. Pfreundschuh CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Blood, April 23, 2009; 113(17): 3896 - 3902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Brugieres, M.-C. Le Deley, A. Rosolen, D. Williams, K. Horibe, G. Wrobel, G. Mann, J. Zsiros, A. Uyttebroeck, I. Marky, et al. Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group J. Clin. Oncol., February 20, 2009; 27(6): 897 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Bernstein, J. M. Unger, M. LeBlanc, J. Friedberg, T. P. Miller, and R. I. Fisher Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516--The Southwest Oncology Group J. Clin. Oncol., January 1, 2009; 27(1): 114 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Arai, S. Ushijima, H. Tsuda, H. Fujimoto, F. Hosoda, T. Shibata, T. Kondo, I. Imoto, J. Inazawa, S. Hirohashi, et al. Genetic Clustering of Clear Cell Renal Cell Carcinoma Based on Array-Comparative Genomic Hybridization: Its Association with DNA Methylation Alteration and Patient Outcome Clin. Cancer Res., September 1, 2008; 14(17): 5531 - 5539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pfreundschuh, C. Zwick, S. Zeynalova, U. Duhrsen, K.-H. Pfluger, T. Vrieling, R. Mesters, H.-G. Mergenthaler, H. Einsele, M. Bentz, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Ann. Onc., March 1, 2008; 19(3): 545 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report Blood, February 1, 2008; 111(3): 1085 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W.M. Johnson and A. J. Davies Primary Mediastinal B-Cell Lymphoma Hematology, January 1, 2008; 2008(1): 349 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Bjorkholm, H Hagberg, H Holte, S Kvaloy, L Teerenhovi, H Anderson, E Cavallin-Stahl, J Myhre, H Pertovaara, A Ost, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up Ann. Onc., June 1, 2007; 18(6): 1085 - 1089. [Abstract] [Full Text] [PDF]
|
|